Myron Czuczman

..A further study is underway to determine whether similar efficacy with less overall toxicity can be achieved using rituximab in combination with fludarabine...

..To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naive or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma...

..To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy...

..Future research is geared to identify drugs and/or biological agents that are effective against RRCL...

..This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma...

..The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy...

..New treatment strategies and novel anti-CD20 mAbs have the potential to enhance long-term outcomes for CLL and NHL...

..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule...

..This report summarizes the latest advances in our understanding of FL and HL, and demonstrates the different approaches required when developing novel treatment strategies for the two diseases...

..CONCLUSION: Although a cure has not been found yet for follicular NHL, the R-CHOP combination provides a lengthy response duration in patients with relapsed or newly diagnosed indolent NHL...

..In this report we provide an overview of recent developments in target-specific therapies and review past, ongoing, and future research tiling this diverse group of exciting novel agents...

..In an attempt to define strategies to overcome rituximab resistance, we sought to determine the chemotherapy sensitivity of our rituximab-resistant cell lines (RRCL)...

..Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review...

..One approach to the development of innovative strategies for treatment of NHL has been the generation of monoclonal antibodies to specific B-cell antigens expressed on NHL cells...

..The crucial data presented at the 2009 ASH annual meeting are discussed and evaluated by 2 leading experts in the treatment of NHL, Drs. Myron S. Czuczman and Mathias J. Rummel...

..The combination of rituximab with conventional chemotherapeutic agents such as CHOP appears to be a viable treatment option for indolent NHL. Ongoing and planned studies will lead to the optimal use of rituximab for the treatment of NHL...

..Augmenting NK cell function by CC-4047 or CC-5013 exposure may increase the antitumor effects of rituximab against B-cell lymphomas and warrants further exploration in the context of a clinical trial...

..Strategies that improve the function of neutrophils, such as granulocyte-macrophage colony-stimulating factor or G-CSF priming, may increase the antitumor effects of rituximab. Additional in vivo animal studies are warranted...

..Our current data provides a basis for further evaluation of alemtuzumab-based clinical trials for patients with rituximab-resistant NHL...

..This two-part review summarizes treatment options for patients with relapsed/refractory DLBCL and stresses the emerging therapeutic challenges for patients who were previously exposed to rituximab...

..The purpose of the current study was to determine the incidence, presentation, and management of patients with NHL of the colon or rectum...

..These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise...

..Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL...

..Theoretically, synergistic antitumor activity should be observed by combining TRAIL-R mAbs with agents (e.g., rituximab) that activate the intrinsic apoptotic pathway...

..Ongoing and future studies are warranted to further evaluate the therapeutic role of galiximab in the treatment of patients with B-cell lymphomas in combination with rituximab or systemic chemotherapy...

..1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma...

..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...

..The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed...

..In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown...

..48--1.17). Other studies have demonstrated that acetaminophen is associated with transient decreases in DNA repair, and lymphocytes may be particularly susceptible to DNA damage, suggesting a mechanism for the elevated NHL risk observed...

....

..Durable antitumor responses have been achieved, even in heavily pretreated patients. The optimal position that these novel agents should take in the algorithm of lymphoma therapy remains to be defined...

..An ongoing phase 2 part of this study will help validate the clinical efficacy of this regimen...

..As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms...

..At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL...

..This report examines the incidence of and risk factors for allogeneic BMT-associated TM in two patient cohorts treated before and after changes in myeloablative conditioning regimen intensity (high vs. standard intensity)...

..CD80 serves as an attractive target in the continued development of mAbs against lymphoma...

..In particular, patients with diffuse large B-cell lymphoma responded well to dacetuzumab; the drug is being pursued for this indication in phase II trials...

..Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice...

..Our positive preclinical data adds additional support for the evaluation of IMiDs plus rituximab in patients with relapsed/refractory B-cell lymphoma...

..The predominance of coagulative necrosis in our series may reflect the high doses of corticosteroids used to treat graft-versus-host disease (GVHD), which may have disabled leukocyte trafficking and hyphal killing...

..Some of the drug classes examined here are proteasome inhibitors, inhibitors of the protein mammalian target of rapamycin (mTOR), the unique alkylating agent bendamustine, and immunomodulatory agents...

..3%) compared to rituximab alone (13.3%) or in combination with peg-GM-CSF (26.7%). Increasing neutrophil counts via cytokine stimulation may play an important role in augmenting rituximab-associated antitumor activity...

..In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics...

..In this review article, we will provide an overview of various rituximab-associated cytotoxic mechanisms and novel strategies to improve mAb activity against B-cell lymphoma...

..However, a high expression of specific antigens on a given B-cell malignancy may potentially identify optimal therapeutic targets for current and/or future monoclonal antibody-based therapies...

..Further investigation of this finding is necessary to further our understanding of the heterogeneous group of ALK- lymphomas...

....

..Czuczman, Head, Lymphoma and Myeloma Service and Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute, Buffalo, NY, on behalf of the Scientific Advisory Committee, to corporate sponsors, speakers and attendees...

....

..Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL...

....

..Rituximab is therefore an excellent treatment option both as first-line and as salvage therapy for patients with indolent NHL...

....

..Of particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict therapeutic responses...

..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...

..Chemotherapy-related anemia is prevalent among patients with hematologic malignancies. A randomized, open-label, multicenter trial of early versus late epoetin alfa in this population was conducted, focusing on quality of life (QOL)...

..Median survival was 5 months for the no-HAART group and 30 months for the HAART group. CONCLUSION: In patients with GI-ARL who were treated with chemotherapy, concurrent therapy with HAART therapy was associated with improved survival...

..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...

....

....